SNMMI image of the year: PSMA PET imaging of theranostic for advanced prostate cancer

(Society of Nuclear Medicine and Molecular Imaging) Studies of patients with metastatic castrate-resistant prostate cancer have demonstrated high response rates to radionuclide therapy targeting PSMA with the radionuclide lutetium-177. At the SNMMI Annual Meeting, researchers reported on a phase II prospective trial. Men who had exhausted conventional therapies were screened using gallium-68-PSMA11 PET imaging. Those with high PSMA-expression had 177Lu-PSMA617 therapy and experienced high response rates, which is clearly shown in the figure selected as the 2018 SNMMI Image of the Year.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news